CHMP Positive Opinion for Trodelvy in 1L Metastatic TNBC for Patients Not Candidates for PD-(L)1 Inhibitors June 2, 2026
Ph 3 Trial of Sacituzumab Tirumotecan (sac-TMT) vs Chemo as 1L Treatment for Advanced TNBC Met Primary Endpoint of PFS May 26, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
Combo Regimen May Improve Pathologic Complete Response Rate in TNBC in Early Ph 2 INVINCIBLE-4 of INT230-6 March 17, 2026
Positive Ph 3 Interim Topline Results for izalontamab brengitecan (Iza-bren) in Unresectable Locally Advanced or Metastatic 1L TNBC Highlighted March 3, 2026
DATROWAY Supplemental NDA Submitted in Japan for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy February 25, 2026
DATROWAY® Granted Priority Review in the US in 1L Metastatic TNBC Patients Who Are Not Candidates for Immunotherapy February 9, 2026
Trodelvy® Added as Preferred Regimen Within 1L Metastatic TNBC in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) February 1, 2026
NEJM Publishes Ph 3 ASCENT-04/KEYNOTE-D19 Results of Trodelvy + Keytruda in 1L PD-L1+ Metastatic TNBC January 25, 2026
DATROWAY® Type II Variation Application Validated in the EU for Patients with 1L Metastatic, IO-ineligible TNBC December 22, 2025
Pan Cancer T Secures EUR 10M to Advance First-in-Human Trial of PCT1:CO-STIM in TNBC December 15, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemo as 1L Treatment for TNBC Presented December 15, 2025
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for TNBC December 9, 2025
No median OS difference observed in TNBC patients treated with nadunolimab + gemcitabine/carboplatin (GC) vs GC in Ph 1b/2 TRIFOUR study December 9, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
